10-Q: Autolus Q2: US Sales Begin, Europe Stalls

Autolus Therapeutics reports initial US product revenue for AUCATZYL but faces significant commercialization hurdles in Europe and increased net losses.

Summary

• Autolus Therapeutics generated $20.9 million in net product revenue from AUCATZYL sales in the United States during Q2 2025, with $29.9 million for the six months ended June 30, 2025.
• The company reported a net loss of $47.9 million for Q2 2025, compared to $58.3 million for Q2 2024, and a net loss of $118.1 million for the six months ended June 30, 2025, up from $111.0 million for the same period in 2024.
• Selling, general and administrative expenses increased by $19.7 million to $59.8 million for the six months ended June 30, 2025, driven by commercialization efforts.
• Research and development expenses decreased by $13.1 million to $54.2 million for the six months ended June 30, 2025, partly due to reallocation of costs to commercial manufacturing and lower UK R&D tax credits.
• Cash and cash equivalents, along with marketable securities, totaled $454.3 million as of June 30, 2025, down from $588.0 million at December 31, 2024.
• Net cash used in operating activities increased to $148.3 million for the six months ended June 30, 2025, compared to $91.6 million for the same period in 2024.
• The UK MHRA granted conditional marketing authorization for AUCATZYL in April 2025, but NICE issued a preliminary recommendation against NHS funding.
• The European Commission granted marketing authorization for AUCATZYL in July 2025, but the company has put the launch in Germany on hold and anticipates no EU sales in 2025 and 2026.
• Autolus voluntarily withdrew obe-cel from the EU register of orphan medicinal products in June 2025.
• Updated long-term data from the FELIX study for obe-cel in r/r B-ALL showed a median duration of response of 42.5 months and 24-month Event Free Survival of 43%, with no new safety signals.
• Preliminary Phase 1 data for obe-cel in lupus nephritis (CARLYSLE study) supports progression to a Phase 2 pivotal study, with FDA alignment on trial design and potential registrational path.
• The BioNTech Manufacturing and Commercial Services Agreement (MCSA) option expired unexercised in August 2025.

Sentiment

Score: 4

Explanation: While the US commercial launch of AUCATZYL is a positive step and clinical data remains strong, significant commercialization headwinds in the UK and EU, coupled with increased net losses and cash burn, indicate a challenging financial outlook. The loss of EU orphan drug status and the unexercised BioNTech option further dampen sentiment, outweighing the positive clinical progress in autoimmune programs.

Positives

• Successfully launched AUCATZYL in the United States, generating initial product revenue of $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025.
• Achieved significant market access in the US, with coverage secured for greater than 90% of total US medical lives for AUCATZYL.
• Activated 46 cancer treatment centers in the United States for AUCATZYL administration.
• Presented positive updated long-term data from the FELIX study for obe-cel in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL), showing a median duration of response of 42.5 months and a 24-month Event Free Survival of 43%.
• Preliminary Phase 1 data for obe-cel in lupus nephritis (CARLYSLE study) supports progression to a Phase 2 pivotal study, demonstrating pipeline advancement beyond oncology.
• Aligned with the U.S. Food and Drug Administration (FDA) on the Phase 2 trial design and potential registrational path for obe-cel in lupus nephritis, indicating a clear regulatory strategy.
• Plans to advance obe-cel into clinical development for progressive multiple sclerosis, further diversifying the pipeline into autoimmune diseases.

Negatives

• Net loss increased to $118.1 million for the six months ended June 30, 2025, compared to $111.0 million for the same period in 2024, indicating higher operating expenses.
• Net cash used in operating activities significantly increased to $148.3 million for the six months ended June 30, 2025, from $91.6 million in the prior year, reflecting increased cash burn.
• Cash and cash equivalents, along with marketable securities, decreased by $133.7 million from December 31, 2024, to June 30, 2025.
• The National Institute for Health and Care Excellence (NICE) issued a preliminary recommendation against NHS funding for AUCATZYL in the United Kingdom, posing a significant hurdle for commercial launch there.
• EU commercial launch of AUCATZYL in Germany is on hold, and no EU sales are anticipated in 2025 and 2026, limiting international revenue potential.
• Voluntarily withdrew obe-cel from the EU register of orphan medicinal products, which may impact commercial viability and pricing in Europe.
• The BioNTech Manufacturing and Commercial Services Agreement (MCSA) option expired unexercised, indicating a missed opportunity for a potential collaboration.
• The CMS policy to split the therapeutic dose of AUCATZYL into two administrations for coding and billing purposes may delay revenue recognition from a particular treatment.
• No longer eligible for the UK SME R&D tax credit scheme, transitioning to the merged RDEC scheme from January 1, 2025, which will result in lower tax credits (up to 15-16.2% vs. 18.6-33.35%).

Risks

• Government price controls in certain jurisdictions may affect the ability to receive adequate coverage and reimbursement for AUCATZYL, making profitable sales difficult.
• The current U.S. presidential administration's policies to reduce regulations and expenditures across government agencies (HHS, FDA, CMS) could create additional uncertainty for the business.
• The CMS policy to bill AUCATZYL's therapeutic dose in two administrations may delay revenue recognition for the company and treatment centers.
• Failure to obtain or maintain benefits associated with orphan drug designation, including market exclusivity or favorable pricing, could reduce sales and negatively impact financial condition.
• International trade policies, including tariffs, sanctions, and trade barriers, could materially increase costs, reduce profitability, and create supply chain delays.
• The successful development and commercialization of product candidates is highly uncertain, with no guarantee of regulatory approval or material net cash inflows.
• Significant competition and rapidly changing technologies within the biopharmaceutical industry pose ongoing challenges.
• The company will need significant additional capital to fund operations until profitability is achieved, and there is no assurance that additional funding will be available on favorable terms or at all.
• Changes in the UK R&D tax credit regime (moving from SME to merged RDEC) will result in lower cash benefits, impacting financial resources.

Future Outlook

The company anticipates commercial launch of AUCATZYL in the United Kingdom in the second half of 2025, subject to a positive recommendation from NICE. EU commercial launch in Germany is on hold, with no EU sales anticipated in 2025 and 2026. The company plans to dose the first patient in a Phase 2 clinical trial for obe-cel in lupus nephritis and a Phase 1 dose escalation clinical trial for obe-cel in progressive multiple sclerosis by year-end 2025. The company expects its current cash and marketable securities to fund operations for at least twelve months from August 12, 2025, but acknowledges the need for significant additional capital to support future development and commercialization efforts.

Management Comments

• "We have 46 cancer treatment centers fully activated in the United States as of August 12, 2025."
• "Patient access to AUCATZYL continues to increase, with coverage secured for greater than 90% of total United States medical lives."
• "We plan to respond to NICE’s questions and will continue to work towards a pathway for patient access to therapy in the United Kingdom."
• "Evaluation of potential pricing and feasibility of market entry opportunities in certain EU countries is ongoing; however, at this time, launch in Germany is on hold and we do not anticipate any EU sales of AUCATZYL in 2025 and 2026."
• "These results suggest that obe-cel may be a durable treatment option for some patients with r/r B-ALL."
• "The Company has aligned with the U.S. Food and Drug Administration (the FDA) on the Phase 2 trial design and potential registrational path to approval and continues to anticipate dosing the first patient in a Phase 2 clinical trial before the end of 2025."
• "We plan to advance obe-cel into clinical development in progressive MS. We continue to expect to dose our first patient in a Phase 1 dose escalation clinical trial by year-end 2025."
• "Our translational programs with University College London (UCL) continue to fuel our early-stage pipeline, providing a cost-efficient path to development."

Industry Context

Autolus Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on CAR T-cell therapies for cancer and autoimmune diseases. The successful commercial launch of AUCATZYL in the US positions Autolus as an early commercial-stage company, a significant step in the CAR T space. However, the challenges faced in the UK (NICE recommendation against funding) and EU (launch on hold, loss of orphan drug status) highlight the complex and often restrictive reimbursement and regulatory landscape for advanced therapies in international markets. The expansion of obe-cel into autoimmune indications like lupus nephritis and multiple sclerosis aligns with a broader industry trend of exploring CAR T beyond oncology, potentially opening new, large markets and diversifying revenue streams, which is crucial given the high development costs and competitive pressures in oncology.

Comparison to Industry Standards

• The 24-month Event Free Survival (EFS) of 43% and Overall Survival (OS) of 46% for obe-cel in r/r B-ALL from the FELIX study suggest a durable treatment option, which is competitive within the CAR T-cell therapy landscape for this aggressive leukemia. For comparison, other approved CAR T therapies for B-ALL, such as Kymriah (tisagenlecleucel) in pediatric and young adult r/r B-ALL, have reported complete remission rates of around 81% and 12-month EFS of 50% in its pivotal ELIANA trial, though direct adult r/r B-ALL comparisons are complex due to patient population differences.
• The preliminary Phase 1 data for obe-cel in lupus nephritis supporting progression to a Phase 2 pivotal study is a positive indicator, as CAR T therapies are still nascent in autoimmune diseases. Companies like Kyverna Therapeutics (KYV-101) and Cabaletta Bio (CABA-201) are also developing CD19-targeted CAR T therapies for autoimmune conditions like lupus nephritis, with early data showing promising safety and efficacy profiles. Autolus's alignment with the FDA on Phase 2 trial design for LN suggests a clear regulatory path, which is a critical benchmark for de-risking clinical development in this emerging area.
• The company's ability to secure coverage for over 90% of US medical lives for AUCATZYL is a strong commercial achievement, comparable to market access efforts seen with other newly launched high-cost therapies, demonstrating effective payer engagement.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceedings that could have an adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Blackstone (BXLS V Autobahn L.P.) is a related party, owning more than 5% of the company's outstanding voting securities and having nominated a director. As of June 30, 2025, the carrying amount of the Blackstone Collaboration Agreement Liability was $212.6 million.
• BioNTech SE is a related party, owning more than 10% of the company's outstanding voting securities and having the right to nominate a director (not yet exercised). As of June 30, 2025, the carrying amount of the BioNTech Liability was $38.0 million.

Stakeholder Impact

• **Shareholders**: Initial product revenue from AUCATZYL in the US is positive, but increased net losses and cash burn, coupled with commercialization challenges in Europe, may impact profitability and share price. The potential need for future capital raises could lead to dilution.
• **Employees**: The adoption of the 2025 Employee Share Purchase Plan provides a new incentive and retention mechanism, allowing employees to purchase shares.
• **Customers (Authorized Treatment Centers)**: The CMS policy splitting AUCATZYL's billing into two administrations may introduce complexities and potential delays in revenue recognition for treatment centers.
• **Patients**: Continued progress in clinical trials for autoimmune diseases (lupus nephritis, multiple sclerosis) offers potential new treatment options. However, the preliminary negative recommendation from NICE in the UK and the on-hold EU launch for AUCATZYL could limit patient access in those regions.
• **Suppliers/Creditors**: Increased cash burn and capital commitments indicate ongoing operational needs, which could benefit suppliers. The company's liquidity position is deemed sufficient for at least 12 months, providing some stability for creditors.

Next Steps

• Respond to NICE's questions and continue efforts towards securing NHS funding for AUCATZYL in the United Kingdom.
• Evaluate potential pricing and feasibility of market entry opportunities in other EU countries for AUCATZYL.
• Dose the first patient in a Phase 2 clinical trial for obe-cel in lupus nephritis before the end of 2025.
• Present longer-term follow-up data from the Phase 1 CARLYSLE clinical trial at a medical conference in the second half of 2025.
• Dose the first patient in a Phase 1 dose escalation clinical trial for obe-cel in progressive multiple sclerosis by year-end 2025.

Key Dates

Recommendation

While Autolus has achieved a significant milestone with the US commercial launch of AUCATZYL and presented promising long-term clinical data, the financial results show increased losses and cash burn. The substantial commercialization hurdles in the UK (NICE rejection) and EU (launch on hold, loss of orphan drug status) create significant uncertainty regarding future revenue growth from AUCATZYL outside the US. The expansion into autoimmune indications is a positive long-term strategic move, but these programs are still in early stages. Given the mixed operational performance and the need for future capital, a 'hold' recommendation is appropriate to observe how the company navigates these commercial challenges and progresses its pipeline.

Keywords

CAR T-cell therapy, Oncology, Acute Lymphoblastic Leukemia, Autoimmune Diseases, Lupus Nephritis, Multiple Sclerosis, Biopharmaceutical, SEC Filing, Clinical Trials, Commercialization, Regulatory Approval, AUCATZYL, obe-cel, Biotech, Healthcare